Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib + Chemotherapy in Advanced pMMR Endometrial Cancer
NCT07170982Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Oct 2025
- Primary completion
- Oct 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fruquintinib in endometrial cancer (EC) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Objective Response Rate at 3 years. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
fruquintinib
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT07170982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07170982.